menu

Is It PAH or PH Due to Lung Disease and/or Chronic Hypoxia?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Is It PAH or PH Due to Lung Disease and/or Chronic Hypoxia?

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    It can be very challenging to differentiate between WHO Class 1 Pulmonary Arterial Hypertension and WHO Class 3 Pulmonary Hypertension due to Lung Disease or Chronic Hypoxia. Despite similar clinical manifestations, these two conditions are characterized by different hemodynamic definitions and etiologies. Through the use of 2 case studies, clinicians can learn about the diagnosis and management of PAH versus PH due to lung disease or chronic hypoxia.

  • Disclosure of Conflicts of Interest

    FACULTY AND PEER REVIEWER DISCLOSURES
    Dr. Channick has disclosed the following relevant financial relationships:
    Advisory Committee: Bayer, Janssen
    Consultant: Arena Pharmaceuticals, Bayer, Gosssamer Bio, Janssen, Third Pole Therapeutics, United Therapeutics
    Contracted Research: Janssen, United Therapeutics
    Speaker: Bayer, Janssen 

    Dr. McLaughlin has disclosed the following relevant financial relationships:
    Consultant: Acceleron, Aerovate, Altavant, Bayer, Caremark, Civi Biopharma, Corvista, Gossamer Bio, Janssen, Merck , United Therapeutics
    Contracted Research: Acceleron, Janssen, Sonovie, United Therapeutics

    Nadine Al-Naamani, MD, MS - Peer Reviewer: has no financial relationships to disclose.

    AKH STAFF AND PLANNERS DISCLOSURES
    Lynne Kolton Schneider, PhD,, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.

    ATS STAFF DISCLOSURES
    Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose.

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    This activity is designed for an audience of physicians, nurse practitioners, and other healthcare professionals.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Identify the clinical presentation, hemodynamic definitions, and diagnosis of pulmonary arterial hypertension and pulmonary hypertension due to lung disease and/or chronic hypoxia
    • Evaluate the recommended treatment for pulmonary arterial hypertension
    • Individualize treatment plans for patients with pulmonary arterial hypertension
  • Accreditation and Credit Designation Statements

    CME Credit provided by The American Thoracic Society

    Physicians
    CME Accreditation Statement
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME Credit Designation Statement
    The American Thoracic Society designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Nurse Practitioners
    This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and The American Thoracic Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1 contact hour(s) (which includes 0.5 hour(s) of pharmacology).

    Criteria for Success
    To receive credit, participants should review the entire activity, complete and submit posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Disclaimer

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclosure Declaration
    It is the policy of ATS and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    It can be very challenging to differentiate between WHO Class 1 Pulmonary Arterial Hypertension and WHO Class 3 Pulmonary Hypertension due to Lung Disease or Chronic Hypoxia. Despite similar clinical manifestations, these two conditions are characterized by different hemodynamic definitions and etiologies. Through the use of 2 case studies, clinicians can learn about the diagnosis and management of PAH versus PH due to lung disease or chronic hypoxia.

  • Disclosure of Conflicts of Interest

    FACULTY AND PEER REVIEWER DISCLOSURES
    Dr. Channick has disclosed the following relevant financial relationships:
    Advisory Committee: Bayer, Janssen
    Consultant: Arena Pharmaceuticals, Bayer, Gosssamer Bio, Janssen, Third Pole Therapeutics, United Therapeutics
    Contracted Research: Janssen, United Therapeutics
    Speaker: Bayer, Janssen 

    Dr. McLaughlin has disclosed the following relevant financial relationships:
    Consultant: Acceleron, Aerovate, Altavant, Bayer, Caremark, Civi Biopharma, Corvista, Gossamer Bio, Janssen, Merck , United Therapeutics
    Contracted Research: Acceleron, Janssen, Sonovie, United Therapeutics

    Nadine Al-Naamani, MD, MS - Peer Reviewer: has no financial relationships to disclose.

    AKH STAFF AND PLANNERS DISCLOSURES
    Lynne Kolton Schneider, PhD,, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.

    ATS STAFF DISCLOSURES
    Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose.

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    This activity is designed for an audience of physicians, nurse practitioners, and other healthcare professionals.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Identify the clinical presentation, hemodynamic definitions, and diagnosis of pulmonary arterial hypertension and pulmonary hypertension due to lung disease and/or chronic hypoxia
    • Evaluate the recommended treatment for pulmonary arterial hypertension
    • Individualize treatment plans for patients with pulmonary arterial hypertension
  • Accreditation and Credit Designation Statements

    CME Credit provided by The American Thoracic Society

    Physicians
    CME Accreditation Statement
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME Credit Designation Statement
    The American Thoracic Society designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Nurse Practitioners
    This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and The American Thoracic Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1 contact hour(s) (which includes 0.5 hour(s) of pharmacology).

    Criteria for Success
    To receive credit, participants should review the entire activity, complete and submit posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Disclaimer

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclosure Declaration
    It is the policy of ATS and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule20 Jan 2022
Webpack App